UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/582,823	06/14/2006	Kenneth L. Arrington	21439YP	7413
210 MERCK	7590 06/23/201	0	EXAM	IINER
PO BOX 2000	07075 0007		TRUONG, TAMTHOM NGO	
RAHWAY, NJ	0/065-090/		ART UNIT	PAPER NUMBER
			1624	
			MAIL DATE	DELIVERY MODE
			06/23/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/582,823	ARRINGTON ET AL.		
Office Action Summary	Examiner	Art Unit		
	TAMTHOM N. TRUONG	1624		
The MAILING DATE of this communic Period for Reply	cation appears on the cover sheet wi	th the correspondence address		
A SHORTENED STATUTORY PERIOD FOWHICHEVER IS LONGER, FROM THE MA  - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commu.  - If NO period for reply is specified above, the maximum stathen a specified above, the maximum stathen and the second period for reply within the set or extended period for reply and any reply received by the Office later than three months after the second patent term adjustment. See 37 CFR 1.704(b).	AILING DATE OF THIS COMMUNIC of 37 CFR 1.136(a). In no event, however, may a re unication. utory period will apply and will expire SIX (6) MON will, by statute, cause the application to become AB	CATION.  Exply be timely filed  THS from the mailing date of this communication.  ANDONED (35 U.S.C. § 133).		
Status				
Responsive to communication(s) filed     This action is <b>FINAL</b> . 2     Since this application is in condition for closed in accordance with the practice.	b)⊡ This action is non-final. or allowance except for formal matte	-		
Disposition of Claims				
4) ☐ Claim(s) 2-8,10 and 11 is/are pending 4a) Of the above claim(s) is/are 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 2-8, 10 and 11 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restrict.	e withdrawn from consideration.			
Application Papers				
9) The specification is objected to by the 10) The drawing(s) filed on is/are:  Applicant may not request that any object Replacement drawing sheet(s) including 11) The oath or declaration is objected to	a) accepted or b) objected to be to to the drawing(s) be held in abeyan the correction is required if the drawing(	ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PT 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	O-948) Paper No(s	ummary (PTO-413) )/Mail Date Iformal Patent Application 		

Application/Control Number: 10/582,823 Page 2

Art Unit: 1624

## **FINAL ACTION**

Applicant's amendment of 4-6-10 has been fully considered. The cancellation of claims 1, 9 and 12-34 has overcome the previous 102 rejections based on **Heider et. al.** (US'788), **Aldag et. al.** (US'448), **Yale et. al.** (US'778), **Wang et. al.** (Bioorg. & Med. Chem. Lett., 2002), **Griffin et. al.** (J. Med. Chem., 1998), **Cruickshank et. al.** (J. Med. Chem., 1974). However, the amended claims have necessitated new ground of rejection.

Claims 2-8, 10 and 11 are pending.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Art Unit: 1624

Claims 2-8, 10 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over **Yale et. al.** In column 2, Example 5 describes the compound of "2,3-dihydro-2-phenyl-3-(2,6-xylyl)-4(1H)-quinazolinone" which has the following structure:

The disclosed compound has *phenyl* groups at the 2- and 3- positions, and can inhibit cell growth which suggests treating cancer. The disclosed compound differs from the claimed compound by not having a substituted *phenyl* group at the 2-position, but such a substituted phenyl group at that position can be found in Example 2. The phenyl at the 3-position is a 2,6- xylyl, which is a position isomer of the one in formula II (i.e.,  $(3-R^{4b}-4-R^{4a})$ -phenyl). Thus, the instant subgenus formula II is clearly suggested by Yale in the generic formula I where possible permutations can have substituted phenyl groups at 2- and 3- positions, see the following excerpt:

Art Unit: 1624

This invention relates to novel substituted 2,3-dihydro-4(1H)-quinazolinones of the formula

wherein R is selected from the group consisting of phenyl, o-chlorophenyl, p-chlorophenyl, trans-2-phenethenyl and 2-thenyl and R' is selected from the group consisting of hydrogen and 2,6-xylyl, provided that R' is 2,6-xylyl only when R is phenyl.

Crounse 150 USPQ 554; Ex parte Engelhardt 208 USPQ 343; In re Mehta 146 USPQ 284; In re Norris 84 USPQ 458, and MPEP 2144.09 (February, 2003 Edition) regarding position isomerism. Thus, it would have been obvious at the time the invention was made to expect instant compounds to possess the utility taught by the applied art in view of the close structural similarity outlined above.

**Non-elected subject matter:** This application contains claim 5 which is still drawn to an invention nonelected with traverse in the reply filed on 10-12-09. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

-----

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAMTHOM N. TRUONG whose telephone number is (571)272-0676. The examiner can normally be reached on Monday thru Friday (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Tamthom N. Truong/ Examiner, Art Unit 1624 6-18-10 /James O. Wilson/ Supervisory Patent Examiner, Art Unit 1624